Celldex Raises $300M in Common Stock Offering to Fuel Pipeline Expansion
Event summary
- Celldex Therapeutics priced a $300M public offering of 10.35M shares at $29.00 per share.
- Underwriters have a 30-day option to purchase an additional 1.55M shares.
- Proceeds will fund commercial launch of barzolvolimab, pipeline development, and corporate purposes.
- Offering expected to close on April 6, 2026, subject to customary conditions.
The big picture
This $300M raise positions Celldex to accelerate its mast cell biology-focused pipeline, particularly around barzolvolimab for chronic spontaneous urticaria. The funding comes amid heightened competition in inflammatory disease therapeutics, where successful commercialization will be key to maintaining valuation. The offering's size reflects investor confidence in Celldex's platform approach despite the clinical-stage risks inherent in biotech financings.
What we're watching
- Commercialization Timing
- How quickly Celldex can advance barzolvolimab through regulatory approval and market launch.
- Pipeline Execution
- Whether the company can effectively allocate proceeds across multiple development programs.
- Market Conditions
- The impact of broader biotech sector volatility on Celldex's stock performance post-offering.
Related topics